The copy number variation and stroke (CaNVAS) risk and outcome study.

John W ColeTaiwo AdigunRufus AkinyemiOnoja Matthew AkpaSteven BellBowang ChenJordi Jimenez CondeUxue LazcanoIsrael FernandezMyriam FornageCristina Gallego-FabregaChristina JernMichael KrawczakArne LindgrenHugh S MarkusOlle MelanderMayowa OwolabiKristina SchlichtMartin SöderholmVinodh SrinivasasainagendraCarolina Soriano TárragaMartin StenmanHemant TiwariMargaret CorasanitiNatalie FecteauBeth GuizzardiHaley LopezKevin NguyenBrady J GaynorTimothy O'ConnorO Colin StineSteven J KittnerPatrick McArdleBraxton D MitchellHuichun XuCaspar Grond-Ginsbach

Published in: PloS one (2021)

The CaNVAS study will cost-effectively leverage the numerous advantages of using existing case-control data sets, exploring the relationships between CNV and IS and its subtypes, and outcome at 3 months, in both men and women, in those of African and European-Caucasian descent, this, across the entire adult-age spectrum.

Keyphrases

copy number
mitochondrial dna
case control
atrial fibrillation
dna methylation
gene expression
machine learning
electronic health record